"Le CHU demande aux usagers de présenter à l’entrée de ses sites hospitaliers un « pass sanitaire », pour accéder au CHU. Ces consignes ne s’appliquent pas : - aux urgences adultes, pédiatriques, gynécoobstétriques, odontologiques et ophtalmologiques ; Plus d'infos sur le site internet du CHU"

During the past decade, CHU Estaing conducted 135 clinical trials. In the 10-year time frame, 135 clinical trials started and 23 clinical trials were completed, i.e. on average, 17% percent of trials that started reached the finish line to date. In the past 5 years, 43 clinical trials started and 18 clinical trials were completed. i.e. 41.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CHU Estaing" #1 sponsor was "The Lymphoma Academic Research Organisation" with 21 trials, followed by "Hospices Civils de Lyon" with 14 trials sponsored, "Federation Francophone de Cancerologie Digestive" with 13 trials sponsored, "Gilead Sciences" with 8 trials sponsored and "Centre Hospitalier Universitaire de Nīmes" with 8 trials sponsored. Other sponsors include 123 different institutions and companies that sponsored additional 80 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CHU Estaing" #1 collaborator was "Gilead Sciences" with 5 trials as a collaborator, "Ministry of Health, France" with 5 trials as a collaborator, "AbbVie" with 4 trials as a collaborator, "Acute Leukemia French Association" with 3 trials as a collaborator and "Celgene" with 3 trials as a collaborator. Other collaborators include 79 different institutions and companies that were collaborators in the rest 74 trials.

According to Clinical.Site data, the most researched conditions in "CHU Estaing" are "Multiple Myeloma" (9 trials), "Ulcerative Colitis" (9 trials), "Acute Myeloid Leukemia" (7 trials), "Colorectal Cancer" (5 trials) and "Follicular Lymphoma" (5 trials). Many other conditions were trialed in "CHU Estaing" in a lesser frequency.

Most popular intervention types in "CHU Estaing" are "Drug" (123 trials), "Other" (28 trials), "Procedure" (18 trials), "Biological" (14 trials) and "Device" (12 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (21 trials), "Gemcitabine" (7 trials), "Lenalidomide" (5 trials), "Rituximab" (5 trials) and "Cyclophosphamide" (4 trials). Other intervention names were less common.

The vast majority of trials in "CHU Estaing" are 172 trials for "All" genders, 16 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are 74 active trials in "CHU Estaing". 2 are not yet recruiting, 47 are recruiting, 24 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 93 completed trials in CHU Estaing, undefined suspended trials, and 12 terminated clinical trials to date.

Out of the total trials that were conducted in CHU Estaing, 6 "Phase 1" clinical trials were conducted, 60 "Phase 2" clinical trials and 60 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 7 trials, and there were also 27 trials that are defined as “Not Applicable".